Evandro de Azambuja

List of Publications by Year in Descending Order

192 papers	12,069 citations	49 h-index	107 g-index
213 ext. papers	14,901 ext. citations	7.2 avg, IF	6.14 L-index

#	Paper	IF	Citations
192	Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.. *Breast Cancer Research and Treatment*, **2022**, 192, 457	4.4	0
191	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline BRCA pathogenic variants having a pregnancy after breast cancer. *Cancer Research*, **2022**, 82, PD5-06-PD5-06	10.1	
190	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.. *Expert Opinion on Investigational Drugs*, **2022**, 1-25	5.9	2
189	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.. *European Journal of Cancer*, **2022**, 166, 219-228	7.5	0
188	Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. *ESMO Open*, **2022**, 7, 100501	6	0
187	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. *ESMO Open*, **2021**, 6, 100300	6	1
186	Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean. *Lancet Oncology, The*, **2021**, 22, e488-e500	21.7	1
185	CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. *European Journal of Clinical Investigation*, **2021**, 51, e13535	4.6	3
184	The Exciting New Field of HER2-Low Breast Cancer Treatment. *Cancers*, **2021**, 13,	6.6	20
183	Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. *Journal of the National Cancer Institute*, **2021**,	9.7	5
182	Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. *Current Oncology Reports*, **2021**, 23, 57	6.3	11
181	OncoAlert Round Table Discussions: The Global COVID-19 Experience. *JCO Global Oncology*, **2021**, 7, 455-463	3.7	4
180	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. *Npj Breast Cancer*, **2021**, 7, 67	7.8	1
179	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years Follow-Up. *Journal of Clinical Oncology*, **2021**, 39, 1448-1457	2.2	50
178	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). *European Journal of Cancer*, **2021**, 148, 287-296	7.5	1
177	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. *European Journal of Cancer*, **2021**, 148, 76-91	7.5	10
176	Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer. *New England Journal of Medicine*, **2021**, 384, 2394-2405	59.2	145

175	Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. *Breast*, **2021**, 57, 86-94	3.6	2
174	HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. *Cancers*, **2021**, 13,	6.6	21
173	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. *Expert Opinion on Biological Therapy*, **2021**, 21, 945-962	5.4	4
172	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. *Cancer Discovery*, **2021**, 11, 2796-2811	24.4	10
171	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. *European Journal of Cancer*, **2021**, 144, 351-359	7.5	
170	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. *Journal of Clinical Oncology*, **2021**, 39, 3293-3305	2.2	14
169	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. *Clinical Cancer Research*, **2021**, 27, 5607-5618	12.9	0
168	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. *Critical Reviews in Oncology/Hematology*, **2021**, 163, 103365	7	15
167	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. *Clinical Cancer Research*, **2021**, 27, 6307-6313	12.9	0
166	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. *Breast*, **2021**, 59, 183-192	3.6	4
165	Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?. *Expert Review of Anticancer Therapy*, **2020**, 20, 563-573	3.5	
164	Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. *British Journal of Cancer*, **2020**, 122, 1453-1460	8.7	12
163	The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). *Acta Oncologica*, **2020**, 59, 723-725	3.2	3
162	Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer. *Clinical Breast Cancer*, **2020**, 20, 262-273.e7	3	5
161	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
160	Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. *Critical Reviews in Oncology/Hematology*, **2020**, 149, 102940	7	3
159	Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. *ESMO Open*, **2020**, 5,	6	5
158	HER2-positive advanced breast cancer treatment in 2020. *Cancer Treatment Reviews*, **2020**, 88, 102033	14.4	30

157	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. *International Journal of Cancer*, **2020**, 147, 160-169	7.5	6
156	Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. *European Journal of Cancer*, **2020**, 126, 65-73	7.5	27
155	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. *ESMO Open*, **2020**, 5, e000947	6	37
154	Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. *ESMO Open*, **2020**, 5, e000979	6	1
153	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. *ESMO Open*, **2020**, 5,	6	74
152	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. *ESMO Open*, **2020**, 5,	6	9
151	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. *European Journal of Cancer*, **2020**, 139, 43-50	7.5	147
150	Targeted therapy for breast cancer in older patients. *Journal of Geriatric Oncology*, **2020**, 11, 380-388	3.6	8
149	A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. *Breast Cancer Research and Treatment*, **2020**, 179, 161-171	4.4	16
148	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. *Breast Cancer Research and Treatment*, **2019**, 177, 103-114	4.4	17
147	Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO). *Breast Cancer Research and Treatment*, **2019**, 176, 607-615	4.4	4
146	Denosumab in early-stage breast cancer. *Lancet Oncology, The*, **2019**, 20, e234-e235	21.7	1
145	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919827714	5.4	17
144	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. *Clinical Cancer Research*, **2019**, 25, 3887-3895	12.9	22
143	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. *Clinical Cancer Research*, **2019**, 25, 3581-3588	12.9	36
142	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. *Journal of Clinical Oncology*, **2019**, 37, 105-114	2.2	38
141	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. *Future Oncology*, **2019**, 15, 1823-1843	3.6	9
140	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. *Anticancer Research*, **2019**, 39, 797-802	2.3	

139	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. *Journal of the National Cancer Institute*, **2019**, 111, 86-94	9.7	49
138	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncology, The*, **2019**, 20, 1226-1238	21.7	55
137	Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. *European Journal of Cancer*, **2019**, 118, 169-177	7.5	24
136	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. *European Journal of Cancer*, **2019**, 118, 1-9	7.5	8
135	PERSEPHONE - implications for clinical practice in 2019. *Nature Reviews Clinical Oncology*, **2019**, 16, 663-664	69.4	1
134	Oncofertility counselling in premenopausal women with HER2-positive breast cancer. *Oncotarget*, **2019**, 10, 926-929	3.3	4
133	How I treat metastatic triple-negative breast cancer. *ESMO Open*, **2019**, 4, e000504	6	36
132	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. *Oncologist*, **2019**, 24, e1034-e1043	5.7	4
131	Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. *Annals of Oncology*, **2019**, 30, x27-x42	19.3	40
130	Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer. *Current Opinion in Oncology*, **2019**, 31, 43-51	4.2	5
129	Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. *Breast Cancer Research and Treatment*, **2019**, 174, 27-37	4.4	25
128	Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. *Cancer*, **2019**, 125, 307-316	6.4	44
127	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. *Breast*, **2018**, 39, 14-18	3.6	12
126	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. *Critical Reviews in Oncology/Hematology*, **2018**, 126, 135-144	7	12
125	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 316-324	4	37
124	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). *Breast Cancer Research and Treatment*, **2018**, 168, 631-638	4.4	35
123	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. *Clinical Cancer Research*, **2018**, 24, 3079-3086	12.9	9
122	Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. *Journal of the National Cancer Institute*, **2018**, 110, 426-429	9.7	95

121	Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. *Frontiers in Oncology*, **2018**, 8, 156	5.3	20
120	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, e181564	13.4	8
119	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. *International Journal of Oncology*, **2018**, 52, 424-432	4.4	5
118	Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.. *Journal of Clinical Oncology*, **2018**, 36, 10066-10066	2.2	2
117	An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.. *Journal of Clinical Oncology*, **2018**, 36, 10068-10068	2.2	2
116	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2018**, 62, 123-132	14.4	14
115	Risk factors for the development of brain metastases in patients with HER2-positive breast cancer. *ESMO Open*, **2018**, 3, e000440	6	15
114	In Reply to Belkacemi and Tsoutsou. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 467-468	4	
113	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. *ESMO Open*, **2018**, 3, e000368	6	26
112	Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. *Expert Review of Anticancer Therapy*, **2018**, 18, 629-649	3.5	20
111	Single-agent PARP inhibitors for the treatment of patients with -mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. *ESMO Open*, **2018**, 3, e000361	6	41
110	Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. *Journal of Clinical Oncology*, **2017**, 35, 878-884	2.2	70
109	11 years-follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. *Lancet, The*, **2017**, 389, 1195-1205	40	486
108	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. *Current Treatment Options in Oncology*, **2017**, 18, 4	5.4	13
107	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. *Cancer Treatment Reviews*, **2017**, 57, 8-15	14.4	49
106	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	7
105	The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. *Clinical Cancer Research*, **2017**, 23, 2702-2712	12.9	51
104	Recurrence dynamics of breast cancer according to baseline body mass index. *European Journal of Cancer*, **2017**, 87, 10-20	7.5	27

103	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. *Journal of Clinical Oncology*, **2017**, 35, 1421-1429	2.2	80
102	HER2-positive breast cancer is lost in translation: time for patient-centered research. *Nature Reviews Clinical Oncology*, **2017**, 14, 669-681	19.4	49
101	Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 1205-1215	5.5	1
100	Breast cancer treatment-induced cardiotoxicity. *Expert Opinion on Drug Safety*, **2017**, 16, 1021-1038	4.1	28
99	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. *New England Journal of Medicine*, **2017**, 377, 122-131	59.2	688
98	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *European Journal of Heart Failure*, **2017**, 19, 9-42	12.3	189
97	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. *JAMA Oncology*, **2017**, 3, 227-234	13.4	79
96	Adjuvant trastuzumab: a 10-year overview of its benefit. *Expert Review of Anticancer Therapy*, **2017**, 17, 61-74	3.5	29
95	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. *OncoTargets and Therapy*, **2017**, 10, 3363-3372	4.4	8
94	Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.. *Journal of Clinical Oncology*, **2017**, 35, 512-512	2.2	7
93	Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. *PLoS ONE*, **2017**, 12, e0172351	3.7	6
92	Twenty years of anti-HER2 therapy-associated cardiotoxicity. *ESMO Open*, **2016**, 1, e000073	6	49
91	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. *British Journal of Cancer*, **2016**, 115, 1471-1478	8.7	29
90	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. *Breast Cancer Research and Treatment*, **2016**, 155, 127-32	4.4	6
89	Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries. *Maturitas*, **2016**, 84, 81-8	5	10
88	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. *Journal of Clinical Oncology*, **2016**, 34, 1034-42	2.2	254
87	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. *PLoS ONE*, **2016**, 11, e0154009	3.7	21
86	Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. *Oncotarget*, **2016**, 7, 13209-20	3.3	4

85	Phosphoethanolamine and the danger of unproven drugs. *Ecancermedicalscience*, **2016**, 10, 681	2.7	
84	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). *ESMO Open*, **2016**, 1, e000107	6	8
83	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. *JAMA Oncology*, **2016**, 2, 1040-7	13.4	48
82	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	18
81	Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors □2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. *Journal of Clinical Oncology*, **2015**, 33, 2600-8	2.2	72
80	Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. *European Journal of Cancer*, **2015**, 51, 1481-9	7.5	26
79	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. *JAMA Oncology*, **2015**, 1, 448-54	13.4	359
78	Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. *European Journal of Cancer*, **2015**, 51, 2517-24	7.5	32
77	An update on PARP inhibitors--moving to the adjuvant setting. *Nature Reviews Clinical Oncology*, **2015**, 12, 27-41	19.4	265
76	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. *Clinical Cancer Research*, **2015**, 21, 569-76	12.9	58
75	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. *Journal of Clinical Oncology*, **2015**, 33, 1334-9	2.2	164
74	Cardiotoxicity of systemic agents used in breast cancer. *Breast*, **2014**, 23, 317-28	3.6	44
73	An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case. *European Journal of Cancer*, **2014**, 50, 3089-97	7.5	13
72	Menopausal hormone therapy use in 17 European countries during the last decade. *Maturitas*, **2014** , 79, 287-91	5	33
71	Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. *Journal of Clinical Oncology*, **2014**, 32, 2794-803	2.2	197
70	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. *Lancet Oncology, The*, **2014**, 15, 1137-46	21.7	312
69	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. *Breast*, **2014**, 23, 473-81	3.6	10
68	Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). *Journal of Clinical Oncology*, **2014**, 32, 2159-65	2.2	164

67	Reply to C. Fontanella et al. *Journal of Clinical Oncology*, **2014**, 32, 3459	2.2	1
66	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. *Journal of Clinical Oncology*, **2014**, 32, LBA4-LBA4	2.2	26
65	Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25. *Ecancermedicalscience*, **2014**, 8, 425	2.7	12
64	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. *Lancet, The*, **2013**, 382, 1021-8	40	377
63	Planning cancer control in Latin America and the Caribbean. *Lancet Oncology, The*, **2013**, 14, 391-436	21.7	299
62	18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. *Journal of Nuclear Medicine*, **2013**, 54, 1862-8	8.9	105
61	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *Journal of Clinical Oncology*, **2013**, 31, 860-7	2.2	1023
60	Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. *Breast Cancer Research and Treatment*, **2013**, 139, 13-22	4.4	94
59	Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. *Breast*, **2013**, 22 Suppl 2, S152-5	3.6	69
58	Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. *Breast*, **2013**, 22, 606-15	3.6	75
57	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial. *Breast*, **2013**, 22, 1060-5	3.6	25
56	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). *Lancet Oncology, The*, **2013**, 14, 244-8	21.7	126
55	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. *Cancer Treatment Reviews*, **2013**, 39, 935-46	14.4	259
54	Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP). *Journal of Chemotherapy*, **2013**, 25, 239-46	2.3	3
53	Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. *Journal of Clinical Oncology*, **2013**, 31, 1954-60	2.2	28
52	Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. *Oncologist*, **2013**, 18, 134-40	5.7	21
51	Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. *Journal of Clinical Oncology*, **2013**, 31, 73-9	2.2	176
50	Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. *Journal of Clinical Oncology*, **2013**, 31, 4504-11	2.2	46

49	Clinical practice-changing trials: the HERA study paradigm. *Expert Review of Anticancer Therapy*, **2013**, 13, 1249-56	3.5	4
48	How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer. *Breast Care*, **2013**, 8, 264-9	2.4	2
47	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. *Lancet, The*, **2012**, 379, 633-40	40	964
46	Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer □AuthorsNreply. *Lancet, The*, **2012**, 379, 2238	40	
45	Targeted therapies in breast cancer: are heart and vessels also being targeted?. *Breast Cancer Research*, **2012**, 14, 209	8.3	21
44	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. *Breast Cancer Research*, **2012**, 14, R70	8.3	47
43	Dissecting the heterogeneity of triple-negative breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 1879-87	2.2	304
42	Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond. *Breast Cancer Management*, **2012**, 1, 217-233	0.7	1
41	Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. *Journal of Oncology*, **2012**, 2012, 417673	4.5	62
40	Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). *Breast Cancer Research and Treatment*, **2012**, 133, 387-91	4.4	50
39	Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer. *Current Opinion in Oncology*, **2012**, 24, 612-22	4.2	12
38	Improving quality of life after breast cancer: dealing with symptoms. *Maturitas*, **2011**, 70, 343-8	5	84
37	Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?. *Lancet Oncology, The*, **2011**, 12, 209-11	21.7	18
36	HER2-overexpressing breast cancer: time for the cure with less chemotherapy?. *Current Opinion in Oncology*, **2011**, 23, 547-58	4.2	15
35	Beyond trastuzumab: new treatment options for HER2-positive breast cancer. *Breast*, **2011**, 20 Suppl 3, S20-7	3.6	46
34	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. *European Journal of Heart Failure*, **2011**, 13, 1-10	12.3	295
33	Multifactorial approach to predicting resistance to anthracyclines. *Journal of Clinical Oncology*, **2011**, 29, 1578-86	2.2	143
32	Neoadjuvant chemotherapy and targeted therapies: a promising strategy. *Journal of the National Cancer Institute Monographs*, **2011**, 2011, 116-9	4.8	2

31	Motherhood after breast cancer: searching for la dolce vita. *Expert Review of Anticancer Therapy*, **2011**, 11, 287-98	3.5	31
30	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). *Journal of the National Cancer Institute Monographs*, **2011**, 2011, 147-51	4.8	55
29	Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. *Journal of Clinical Oncology*, **2010**, 28, 3422-8	2.2	203
28	Sequential or concurrent administration of trastuzumab in early breast cancer? Too early to judge. *Journal of Clinical Oncology*, **2010**, 28, e353-4	2.2	6
27	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. *Breast Cancer Research and Treatment*, **2010**, 119, 145-53	4.4	117
26	Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. *Critical Reviews in Oncology/Hematology*, **2010**, 75, 110-21	7	33
25	HER-2 as a target for breast cancer therapy. *Clinical Cancer Research*, **2009**, 15, 1848-52	12.9	32
24	Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. *Current Cancer Drug Targets*, **2009**, 9, 148-62	2.8	44
23	Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. *Journal of Clinical Oncology*, **2009**, 27, 720-5	2.2	19
22	Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. *Journal of Clinical Oncology*, **2009**, 27, 2962-9	2.2	141
21	Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?. *Targeted Oncology*, **2009**, 4, 77-88	5	83
20	Are we HER-ting for innovation in neoadjuvant breast cancer trial design?. *Breast Cancer Research*, **2009**, 11, 201	8.3	8
19	Larotaxel: broadening the road with new taxanes. *Expert Opinion on Investigational Drugs*, **2009**, 18, 1183-9	3.9	46
18	Novel therapeutics in breast cancer□ooking to the future. *Update on Cancer Therapeutics*, **2009**, 3, 189-205		6
17	Jumping higher: is it still possible? The ALTTO trial challenge. *Expert Review of Anticancer Therapy*, **2008**, 8, 1883-90	3.5	41
16	Facts and controversies in the use of trastuzumab in the adjuvant setting. *Nature Clinical Practice Oncology*, **2008**, 5, 645-54		13
15	Current perspectives of epothilones in breast cancer. *European Journal of Cancer*, **2008**, 44, 341-52	7.5	15
14	HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?. *Anti-Cancer Agents in Medicinal Chemistry*, **2008**, 8, 488-96	2.2	24

13	Trastuzumab (herceptin) for early-stage breast cancer. *Hematology/Oncology Clinics of North America*, **2007**, 21, 239-56	3.1	4
12	Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. *Oncologist*, **2007**, 12, 253-70	5.7	75
11	Review: side effects of approved molecular targeted therapies in solid cancers. *Oncologist*, **2007**, 12, 1443-55	5.7	250
10	The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. *Cancer Treatment Reviews*, **2007**, 33, 64-77	14.4	63
9	Molecular targeted therapies in breast cancer: where are we now?. *International Journal of Biochemistry and Cell Biology*, **2007**, 39, 1375-87	5.6	29
8	Long-term survival in pituitary metastasis from breast cancer. *Breast*, **2006**, 15, 446-7	3.6	4
7	Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. *Head and Neck*, **2006**, 28, 256-69	4.2	109
6	Molecular profiling of a tumor of unknown origin. *New England Journal of Medicine*, **2006**, 355, 1071-2	59.2	39
5	Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. *Oncologist*, **2006**, 11, 111-25	5.7	45
4	OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy. *Journal of Clinical Oncology*, **2006**, 24, 5176-7; author reply 5177	2.2	3
3	Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). *Critical Reviews in Oncology/Hematology*, **2006**, 59, 40-50	7	62
2	Pulmonary epithelial permeability in patients treated with bleomycin containing chemotherapy detected by technetium-99m diethylene triamine penta-acetic acid aerosol (99mTc-DTPA) scintigraphy. *Annals of Nuclear Medicine*, **2005**, 19, 131-5	2.5	5
1	Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma. *Journal of Clinical Oncology*, **2005**, 23, 6803-4; author reply 6804-5	2.2	3